<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39351231</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.</ArticleTitle><Pagination><StartPage>1462628</StartPage><MedlinePgn>1462628</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1462628</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1462628</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razavi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raei</LastName><ForeName>Maedeh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirato</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Predictive Medicine and Sport Science, Kyorin University Faculty of Medicine, Mitaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053634">TYK2 Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>156986-95-7</RegistryNumber><NameOfSubstance UI="D053633">Receptor, Interferon alpha-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508033">IFNAR2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C070139">TYK2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053634" MajorTopicYN="Y">TYK2 Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053633" MajorTopicYN="Y">Receptor, Interferon alpha-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS coronavirus 2</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">interferon alpha-beta receptor subunit 2 (IFNAR2)</Keyword><Keyword MajorTopicYN="N">prognostic factor</Keyword><Keyword MajorTopicYN="N">tyrosine kinase</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351231</ArticleId><ArticleId IdType="pmc">PMC11439707</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1462628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Razavi A, Raei M, Hatami Y, Chokami GS, Goudarzi Y, Ghasemian R, et al. . Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study. Front Cell Infection Microbiol. (2024) 14:1356542. doi: 10.3389/fcimb.2024.1356542</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2024.1356542</ArticleId><ArticleId IdType="pmc">PMC11089198</ArticleId><ArticleId IdType="pubmed">38741892</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaei M, Shamshirian A, Monkman J, Grice L, Tran M, Tan CW, et al. . IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study. Front Immunol. (2022) 13:1060438. doi: 10.3389/fimmu.2022.1060438</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1060438</ArticleId><ArticleId IdType="pmc">PMC9850159</ArticleId><ArticleId IdType="pubmed">36685600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. . Genetic mechanisms of critical illness in COVID-19. Nature. (2021) 591:92–8. doi: 10.1038/s41586-020-03065-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. . Mapping the human genetic architecture of COVID-19. Nature. (2021) 600:472–7. doi: 10.1038/s41586-021-03767-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03767-x</ArticleId><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LC, Gomes CEM, Rodrigues-Neto JF, Jeronimo SMB. Genome-wide association studies of COVID-19: Connecting the dots. Infection Genet Evolution: J Mol Epidemiol Evolutionary Genet Infect Dis. (2022) 106:105379. doi: 10.1016/j.meegid.2022.105379</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2022.105379</ArticleId><ArticleId IdType="pmc">PMC9584840</ArticleId><ArticleId IdType="pubmed">36280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, et al. . Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine. (2021) 72:103629. doi: 10.1016/j.ebiom.2021.103629</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103629</ArticleId><ArticleId IdType="pmc">PMC8512556</ArticleId><ArticleId IdType="pubmed">34655949</ArticleId></ArticleIdList></Reference><Reference><Citation>Raftery N, Stevenson NJ. Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway. Cell Mol Life Sci: CMLS. (2017) 74:2525–35. doi: 10.1007/s00018-017-2520-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2520-2</ArticleId><ArticleId IdType="pmc">PMC7079803</ArticleId><ArticleId IdType="pubmed">28432378</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhafez M, Nasereddin A, Shamma OA, Abed R, Sinnokrot R, Marof O, et al. . Association of IFNAR2 rs2236757 and OAS3 rs10735079 Polymorphisms with Susceptibility to COVID-19 Infection and Severity in Palestine. Interdiscip Perspect Infect Dis. (2023) 2023:9551163. doi: 10.1155/2023/9551163</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/9551163</ArticleId><ArticleId IdType="pmc">PMC10517872</ArticleId><ArticleId IdType="pubmed">37745867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. (2020) 369:718–24. doi: 10.1126/science.abc6027</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, et al. . Soluble receptor isoform of IFN-beta (sIFNAR2) in multiple sclerosis patients and their association with the clinical response to IFN-beta treatment. Front Immunol. (2021) 12:778204. doi: 10.3389/fimmu.2021.778204</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.778204</ArticleId><ArticleId IdType="pmc">PMC8716373</ArticleId><ArticleId IdType="pubmed">34975865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaugel-Novoa M, Bourlet T, Longet S, Botelho-Nevers E, Paul S. Association of IFNAR1 and IFNAR2 with COVID-19 severity. Lancet Microbe. (2023) 4:e487. doi: 10.1016/S2666-5247(23)00095-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00095-2</ArticleId><ArticleId IdType="pmc">PMC10072862</ArticleId><ArticleId IdType="pubmed">37028439</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenegro AFL, Clementino MAF, Yaochite JNU. Type I interferon pathway genetic variants in severe COVID-19. Virus Res. (2024) 342:199339. doi: 10.1016/j.virusres.2024.199339</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2024.199339</ArticleId><ArticleId IdType="pmc">PMC10901847</ArticleId><ArticleId IdType="pubmed">38354910</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Bielma MF, Falfán-Valencia R, Abarca-Rojano E, Pérez-Rubio G. Participation of single-nucleotide variants in IFNAR1 and IFNAR2 in the immune response against SARS-coV-2 infection: A systematic review. Pathog (Basel Switzerland). (2023) 12:1320. doi: 10.3390/pathogens12111320</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12111320</ArticleId><ArticleId IdType="pmc">PMC10675296</ArticleId><ArticleId IdType="pubmed">38003785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabihi Rizi F, Ghorbani A, Zahtab P, Darbaghshahi NN, Ataee N, Pourhamzeh P, et al. . TYK2 single-nucleotide variants associated with the severity of COVID-19 disease. Arch Virol. (2023) 168:119. doi: 10.1007/s00705-023-05729-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-023-05729-2</ArticleId><ArticleId IdType="pmc">PMC10035968</ArticleId><ArticleId IdType="pubmed">36959416</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I, Martínez-Morales A, Chávez-Galán L, Ocaña-Guzmán R, Buendía-Roldán I, Pérez-Rubio G, et al. . IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19. Front Immunol. (2022) 13:949413. doi: 10.3389/fimmu.2022.949413</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.949413</ArticleId><ArticleId IdType="pmc">PMC9374460</ArticleId><ArticleId IdType="pubmed">35967349</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I, Martínez-Morales A, Pérez-Rubio G, Buendía-Roldán I, Chávez-Galán L, Hernández-Zenteno R, et al. . Relevance of IFNAR2 variants in the mortality of patients with severe COVID-19. Eur Respir J. (2022) 60:2163. doi: 10.1183/13993003.congress-2022.2163</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.congress-2022.2163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Huang Y, Zhao S, Yao Y, Zhang Y, Qu J, et al. . Integrative genomics analysis reveals a 21q22.11 locus contributing risk to COVID-19. Hum Mol Genet. (2021) 30:1247–58. doi: 10.1093/hmg/ddab125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab125</ArticleId><ArticleId IdType="pmc">PMC8136003</ArticleId><ArticleId IdType="pubmed">33949668</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhung VP, Ton ND, Ngoc TTB, Thuong MTH, Hai NTT, Oanh KTP, et al. . Host genetic risk factors associated with COVID-19 susceptibility and severity in Vietnamese. Genes. (2022) 13:1884. doi: 10.3390/genes13101884</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13101884</ArticleId><ArticleId IdType="pmc">PMC9601961</ArticleId><ArticleId IdType="pubmed">36292769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieter C, de Almeida Brondani L, Lemos NE, Schaeffer AF, Zanotto C, Ramos DT, et al. . Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 genes are associated with worse clinical outcomes in COVID-19. Genes. (2022) 14:29. doi: 10.3390/genes14010029</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14010029</ArticleId><ArticleId IdType="pmc">PMC9858252</ArticleId><ArticleId IdType="pubmed">36672770</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GHL, Justice AE, et al. . Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. (2022) 54:382–92. doi: 10.1038/s41588-021-01006-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-01006-7</ArticleId><ArticleId IdType="pmc">PMC9005345</ArticleId><ArticleId IdType="pubmed">35241825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahranavard-Pirbazari P, Khoshghiafeh A, Kamali MJ, Esfandiar H, Bakhtiari M, Ahmadifard M. A comprehensive review of ACE2, ACE1, TMPRSS2 and IFITM3 gene polymorphisms and their effect on the severity of COVID-19. Adv Med Sci. (2023) 68:450–63. doi: 10.1016/j.advms.2023.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2023.10.010</ArticleId><ArticleId IdType="pubmed">37926001</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. (2021) 27:28–33. doi: 10.1038/s41591-020-01202-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan JA, Abdulrahim JW, Bihlmeyer NA, Haynes C, Kwee LC, Patel MR, et al. . Phenome-wide association study of severe COVID-19 genetic risk variants. J Am Heart Assoc. (2022) 11:e024004. doi: 10.1161/JAHA.121.024004</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.024004</ArticleId><ArticleId IdType="pmc">PMC9075057</ArticleId><ArticleId IdType="pubmed">35179038</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmansour R, Tagajdid M, El Hamzaoui H, Fjouji S, Doghmi N, Houba A, et al. . TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco. Int J Immunopathol Pharmacol. (2024) 38:3946320241257241. doi: 10.1177/03946320241257241</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03946320241257241</ArticleId><ArticleId IdType="pmc">PMC11102656</ArticleId><ArticleId IdType="pubmed">38760017</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao W, Zhang W, Fang X, Yu D, Wang X. Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. J Microbiol Immunol Infection. (2022) 55:387–94. doi: 10.1016/j.jmii.2022.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.03.007</ArticleId><ArticleId IdType="pmc">PMC9040366</ArticleId><ArticleId IdType="pubmed">35501267</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama M, Lucas C, Monteiro VS, Iwasaki A. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proc Natl Acad Sci United States America. (2023) 120:e2221652120. doi: 10.1073/pnas.2221652120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2221652120</ArticleId><ArticleId IdType="pmc">PMC10120007</ArticleId><ArticleId IdType="pubmed">37036977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. . Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. (2020) 251:228–48. doi: 10.1002/path.5471</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5471</ArticleId><ArticleId IdType="pmc">PMC7276767</ArticleId><ArticleId IdType="pubmed">32418199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouremamali A, Babaei A, Malekshahi SS, Abbasi A, Rafiee N. Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. Egyptian J Med Hum Genet. (2022) 23:103. doi: 10.1186/s43042-022-00314-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43042-022-00314-9</ArticleId><ArticleId IdType="pmc">PMC9206724</ArticleId><ArticleId IdType="pubmed">37521846</ArticleId></ArticleIdList></Reference><Reference><Citation>Saponaro F, Rutigliano G, Sestito S, Bandini L, Storti B, Bizzarri R, et al. . ACE2 in the era of SARS-coV-2: controversies and novel perspectives. Front Mol Biosci. (2020) 7:588618. doi: 10.3389/fmolb.2020.588618</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.588618</ArticleId><ArticleId IdType="pmc">PMC7556165</ArticleId><ArticleId IdType="pubmed">33195436</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. (2021) 7:e06187. doi: 10.1016/j.heliyon.2021.e06187</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06187</ArticleId><ArticleId IdType="pmc">PMC7887388</ArticleId><ArticleId IdType="pubmed">33644468</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li W, Liu Z, Kang Y, Zhang X, Xu Z, et al. . A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B. 1.1. 529) on some immune characteristics. Sci Rep. (2022) 12:17058. doi: 10.1038/s41598-022-21690-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21690-7</ArticleId><ArticleId IdType="pmc">PMC9554390</ArticleId><ArticleId IdType="pubmed">36224298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain A, Akter S, Rashid AA, Khair S, Alam ARU. Unique mutations in SARS-CoV-2 Omicron subvariants’ non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. Microbial Pathogenesis. (2022) 170:105699. doi: 10.1016/j.micpath.2022.105699</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2022.105699</ArticleId><ArticleId IdType="pmc">PMC9356572</ArticleId><ArticleId IdType="pubmed">35944840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>